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ABSTRACT 
Background: Concerns about increased mortality could question the role of COPD chronic 
disease management (CDM) programmes. We aimed at extending a recent Cochrane review to 
assess the effects of CDM on mortality in COPD patients. 
Methods: Mortality data was available for 25 out of 29 trials identified in a COPD integrated 
care systematic review. Meta-analysis using random-effects models was performed, followed by 
subgroup analyses according to study length (3-12 months vs >12 months), main intervention 
component (exercise, self-management, structured follow-up), and use of an action plan. 
Results: The meta-analysis showed no impact of CDM on mortality (pooled OR: 1.00, 95% CI 
0.79-1.28).  
Conclusions: These results do not suggest that CDM programmes expose patients with COPD 
to excessive mortality risk.  
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For more than two decades, chronic disease management (CDM) initiatives have been 
developed and implemented in many countries. CDM aims at reorganizing healthcare systems 
and medical treatment to address the increasing burden of chronic diseases and provide solutions 
to organizational, medical and economical problems. A recent Cochrane systematic review 
showed that in COPD patients, CDM significantly improved health-related quality of life as well as 
exercise tolerance (6-minutes walking test-MWT), and decreased the risk of hospitalization.[1] 
While updating non-Cochrane systematic reviews published in the mid-2000s and conducting a 
methodologically sound and rigorous Cochrane systematic review, Kruis et al confirmed previous 
trends in outcomes, indeed. Unfortunately, analyses of secondary outcomes, such as mortality, 
were not performed comprehensively enough from our perspective. In fact, out of 26 studies 
included in the review and three studies awaiting assessment,[2-4] only data from the five 
randomised controlled trials (RCTs) explicitly reporting mortality as an outcome were considered 
in the mortality meta-analysis. Mortality results are of crucial importance for those interested in 
CDM development and implementation in the field, particularly since Fan’s publication in 2012.[3] 
In the latter study in fact, health benefits from such a program were counterbalanced by an 
unexpected and still unexplained significantly higher mortality in COPD patients participating in a 
comprehensive care program.  
 
The aim of our targeted analyses was to assess mortality of COPD patients participating 
in CDM programmes using data from studies included in Kruis’ recent Cochrane review.[1] 
Because all-cause mortality is an indisputable outcome, even if not a targeted study event, we 
considered all 29 RCTs described in Kruis’ review: 26 RCTs meeting Kruis’ operational definition 
of CDM (> 2 different types of healthcare professionals actively involved in patients care, > 2 
intervention components, > 3 months duration) and included in the analyses, as well three studies 
identified as “awaiting assessment”. [1] We reviewed the three latter studies and considered them 
to meet inclusion and exclusion criteria of the systematic review; one of the three was the Fan’s 
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RCT.[3] Mortality data was available for 25 of the 29 eligible studies described in Kruis’ review. 
Baseline number of patients included in both CDM and control groups, number of deaths in each 
group during studies’ periods as well as studies’ length, main intervention component and use of 
action plan, were extracted. We conducted a random-effects meta-analysis, followed by subgroup 
analyses according to study length (3-12 months vs >12 months), main intervention component 
(exercise, self-management, structured follow-up) and specific use of an action plan in the 
intervention. 
Our enriched meta-analysis showed no impact of CDM on overall mortality (25 studies; 
pooled odd ratio (OR): 1.00, 95%CI [0.79-1.28]; Figure). There was little evidence for 
heterogeneity (I2 19%) and only discrete asymmetry as assessed by a funnel plot. All subgroup 
analyses showed non-significant pooled odds ratios. As event rates were low, we also computed 
the unweighted estimate of the pooled OR after adding 0.5 to observed frequencies of all studies, 
as suggested by Bhaumik et al. [5] This methodology allows the inclusion of zero total events and 
has been shown to perform better than the traditional DerSimonian and Laird approach in those 
situations. Results were however similar to the standard ones (pooled OR=1.07 95%CI [0.58-
1.84], between-study variance Tau2=0.4). Varying the between-study variance (0.08≤Tau2≤0.6) 
did not alter the results, thereby illustrating their robustness. 
 Results of this enriched meta-analysis do not suggest that complex interventions such 
as CDM expose patients with COPD to excessive mortality risk, as feared by a recent RCT [3].  
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Figure: Overall mortality forest-plot 
 
 
